Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: a Multicenter Prospective Observational Study (COSMOS-MEL01).
Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molec...